Emcure Pharmaceuticals has received CDSCO approval for its drug Poviztra (Semaglutide) to treat MASH in adults with liver fibrosis. This marks a first-mover advantage for the company in the Indian market.
Emcure Pharmaceuticals Gains First-Mover Advantage with MASH Drug Approval
Emcure Pharmaceuticals Ltd. has secured Central Drugs Standard Control Organisation (CDSCO) approval for its product Poviztra, featuring the innovator drug Semaglutide. This approval is for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3) who do not have cirrhosis.
What just happened
CDSCO has approved Emcure's Poviztra (Semaglutide) for MASH treatment in non-cirrhotic patients with liver fibrosis.
Why this matters
This approval grants Emcure a first-mover advantage in India for a GLP-1 receptor agonist targeting MASH, expanding its metabolic disease portfolio.
The backstory
The approval is backed by global Phase III ESSENCE trial data. These trials showed semaglutide's efficacy, with a 63% resolution rate of steatohepatitis and a 37% improvement in liver fibrosis in patients. Emcure is India's 13th largest pharma company as of March 2026 (MAT).
What changes now
Emcure will commercialize Poviztra for MASH through its subsidiary, Zuventus Healthcare. The company plans to leverage its existing gastroenterology and hepatology products to boost awareness and early diagnosis.
Risks to watch
- Diagnosis Challenges: MASH is often asymptomatic in early stages, requiring significant physician education and market development.
- Supply Chain: The product is manufactured and imported from Novo Nordisk's European facility, creating dependency.
Peer comparison
As the first GLP-1 receptor agonist approved for MASH in India, Emcure establishes a unique market position, though specific peers for this indication in India are still emerging.
Context metrics
Emcure Pharmaceuticals is ranked as the 13th largest pharmaceutical company in India (MAT March 2026).
What to track next
Investors should monitor the commercial rollout by Zuventus Healthcare and the market adoption rate, considering MASH's diagnostic difficulties.